The new weight-loss jab outperforms its competitors, including Ozempic. It helps obese patients lose four stone in under a year.
Retatrutide acts on three receptors in the mind, “turbocharging”, calorie burn while making people full. Weight-loss injections currently available only suppress appetite. The new treatment speeds up metabolism.
Participants in a study presented at the European Congress on Obesity held in Venice lost an average of one quarter of their bodyweight after a period of almost a year. Retatrudide, according to experts, is the most powerful anti-obesity drug. Scientists have dubbed it “Godzilla” among weight loss injections.
After further studies are conducted, the drug could be approved by the NHS for obese patients within three years.
In the trial, 338 obese adults were divided into two groups. Half of them received a weekly injection of retatrutide and the other half received a placebo. After 48 weeks the average weight loss for participants taking the drug was 24 percent, which is equivalent to more than 4 stone. The drug was most effective for women, who lost 28.5% of their bodyweight compared to 21.2% of men. The placebo group lost only 2 percent of their weight.
Retatrutide is superior to the other two weekly weight-loss injections that are available in Britain. Semaglutide was the first injection on the market. It is also known as Ozempic and Wegovy. This injectable mimics a hormone, GLP-1, that causes people to feel full. The second injection, called tirzepatide and sold under the brand name Mounjaro mimics GLP-1, as well as a second hormone that controls appetite called GIP.
Retatrutide increases the rate of burning calories by adding a third hormone, glucagon.
Ania Jastreboff, the director of Yale’s Obesity Research Center said that the results were “striking”, and that retatrutide achieved a “degree” of weight loss not seen before.
Nadia Ahmad from Ely Lilly is overseeing the phase 3 retatrutide trial. She said: “We are very excited about how much weight loss has been achieved with ratatrutide by activating three different receptors. This makes it different than other drugs currently on the market.”
Mounjaro users saw their weight drop by 22.5% in 72 weeks. Wegovy users saw a 15 percent loss over 68 week period. Retatrutide was able to achieve a greater weight loss average — 24 percent of body weight over 48 weeks.
Professor Alexander Miras from Ulster University is an expert in obesity and explains: “Retatrutide basically Mounjaro turbocharged.” The glucagon increases your energy expenditure, or the amount of calories you burn.
There are two mechanisms: decreasing food intake and increasing the energy expenditure. All medications up until now have focused solely on reducing the food intake.
Professor Naveed Satar of Glasgow University who worked on trials for other weight-loss jabs said, “Five or ten year ago, we couldn’t have imagined drugs which would cause such a weight loss.” “That is a huge amount of weight,” he added. There are large trials planned to test whether this can be done safely.
The study published in the New England Journal of Medicine shows that the drug has other health benefits. The blood pressure and sugar levels of the participants improved significantly. Four out of ten participants could stop taking their medication for high blood sugar. Retatrutide, like all other GLP-1 drugs before it, caused side effects such as nausea, diarrhoea, and constipation.
Professor Julio Rosenstock of University of Texas conducted a separate study looking at retatrutide for people with Type 2 Diabetes. He said: “We now know that tirzepatide is the King Kong of GLP-1s. When I look at retatrutide I believe that Godzilla is definitely smiling.
Tens of thousands obese NHS patients receive Wegovy, but due to global shortages only a portion of those who are eligible can take it. Mounjaro, which is available in Britain privately, is also used to treat obesity by the NHS.
The cost of retatrutide is not known, but other weight loss injections can be purchased for about £200 per month.
Post Disclaimer
The following content has been published by Stockmark.IT. All information utilised in the creation of this communication has been gathered from publicly available sources that we consider reliable. Nevertheless, we cannot guarantee the accuracy or completeness of this communication.
This communication is intended solely for informational purposes and should not be construed as an offer, recommendation, solicitation, inducement, or invitation by or on behalf of the Company or any affiliates to engage in any investment activities. The opinions and views expressed by the authors are their own and do not necessarily reflect those of the Company, its affiliates, or any other third party.
The services and products mentioned in this communication may not be suitable for all recipients, by continuing to read this website and its content you agree to the terms of this disclaimer.